Dr. Pereira is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 East 98th St
Icahn School of Medicine at Mount Sinai
New York, NY 10029Phone+1 212-241-7076
Summary
- Dr. Ana Pereira completed her neurology residency at Harvard University, with sub-specialty trainings in cognitive neurology at Columbia University and translational and clinical investigation at Rockefeller University in New York City. Clinically, she evaluates patients at the Center for Cognitive Health at The Mount Sinai Hospital having expertise in diagnosing and treating neurodegenerative disorders and other cognitive syndromes. Dr. Pereira’s research focuses on furthering knowledge of the neurobiology of aging and Alzheimer’s disease, taking into account the selective vulnerability of glutamatergic neural circuits to synaptic changes in aging and neuronal loss in Alzheimer’s disease. She seeks to explore mechanisms underlying these susceptibilities along with effective therapeutic interventions. Dr. Pereira offers telemedicine appointments when appropriate. Please call her office to schedule a video visit.
Lab Website: https://labs.icahn.mssm.edu/pereiralab/
Clinical Website: https://www.mountsinai.org/profiles/ana-pereira
Education & Training
New York-Presbyterian HospitalPost-Doctoral Fellowship, 2012 - 2015
Rockefeller UniversityMS, Translational and Clinical Investigation, 2011 - 2014
Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 2008 - 2011
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2007 - 2008
Universidade de Sao Paulo Faculty of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2011 - 2025- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Riluzole in Mild Alzheimer's Disease Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 878 citationsAn in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus.Ana C. Pereira, Daniel E. Huddleston, Adam M. Brickman, Alexander A. Sosunov, René Hen
Proceedings of the National Academy of Sciences of the United States of America. 2007-03-27 - 30 citationsChronic Intermittent Hypoxia Enhances Pathological Tau Seeding, Propagation, and Accumulation and Exacerbates Alzheimer-like Memory and Synaptic Plasticity Deficits an...Syed Faraz Kazim, Abhijeet Sharma, Sivaprakasam R. Saroja, Joon Ho Seo, Chloe S. Larson
Biological Psychiatry. 2021-03-24 - 15 citationsAcceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.Suzanne E Schindler, Douglas Galasko, Ana C Pereira, Gil D Rabinovici, Stephen Salloway
Nature Reviews. Neurology. 2024-07-01
Journal Articles
- Sex and age differentially affect GABAergic neurons in the mouse prefrontal cortex and hippocampus following chronic intermittent hypoxiaBatsheva R.RubinabTeresa A.MilnerabVirginia M.PickelbChristal G.ColemanbJoseMarques-LopesbTracey A.Van KempenbSyed FarazKazimacdBruce S.McEwenaJason D.GrayaAna C.Pereira, Experimental Neurology, 3/2020
- The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunctionMaria Carmen Inda, Suhasini Joshi, Tai Wang, Alexander Bolaender, Srinivasa Gandu, John Koren III, Alicia Yue Che, Tony Taldone, Pengrong Yan, Weilin Sun, Mohammad Udd..., NAture Communications, 1/16/2020
Press Mentions
Fintepla Reduced Seizures in Those with Developmental and Epileptic EncephalopathiesJune 28th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
